Journal
GUT PATHOGENS
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13099-021-00407-7
Keywords
Angiotensin-converting enzyme 2; Gut-lung axis; Gut-microbiome; Opportunistic pathogens; Probiotics; SARS-CoV-2
Categories
Funding
- Department of Biotechnology under BioCARe scheme [BT/PR30603/BIC/101/1104/2018]
- JC Bose fellowship
Ask authors/readers for more resources
COVID-19 patients may have SARS-CoV-2 present in their nasopharyngeal and stool samples. The gut microbiota plays a crucial role in immune response and could be a significant factor in the prognosis of COVID-19.
COVID-19 is an acute respiratory distress syndrome and is often accompanied by gastrointestinal symptoms. The SARS-CoV-2 has been traced not only in nasopharyngeal and mid-nasal swabs but also in stool and rectal swabs of COVID-19 patients. The gut microbiota is important for an effective immune response as it ensures that unfavorable immune reactions in lungs and other vital organs are regulated. The human gut-lung microbiota interplay provides a framework for therapies in the treatment and management of several pulmonary diseases and infections. Here, we have collated data from COVID-19 studies, which suggest that bacterial co-infections as well as the gut-lung cross talk may be important players in COVID-19 disease prognosis. Our analyses suggests a role of gut microbiome in pathogen infections as well as in an array of excessive immune reactions during and post COVID-19 infection recovery period.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available